Tag Archives: Andrew Fein

Analysts Have Conflicting Sentiments on These Healthcare Companies: Kadmon Holdings (NASDAQ: KDMN), Lineage Cell Therapeutics (NYSE MKT: LCTX) and Ascendis Pharma (NASDAQ: ASND)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kadmon Holdings (KDMN – Research Report), Lineage Cell Therapeutics (LCTX – Research Report) and Ascendis Pharma (ASND – Research Report). TipRanks has tracked

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Bausch Health Companies (BHC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Bausch Health Companies (BHC – Research Report) and Adicet Bio (ACET – Research Report) with bullish sentiments.

H.C. Wainwright Remains a Buy on Fulcrum Therapeutics (FULC)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $11.87. According to TipRanks.com, Fein is

H.C. Wainwright Keeps a Buy Rating on Matinas BioPharma (MTNB)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $1.06. According to TipRanks.com, Fein is

Analysts Offer Insights on Healthcare Companies: I-MAB (NASDAQ: IMAB), Vaxcyte (NASDAQ: PCVX) and Silverback Therapeutics (NASDAQ: SBTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on I-MAB (IMAB – Research Report), Vaxcyte (PCVX – Research Report) and Silverback Therapeutics (SBTX – Research Report) with bullish sentiments. I-MAB (IMAB)

H.C. Wainwright Maintains Their Buy Rating on Kadmon Holdings (KDMN)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kadmon Holdings (KDMN – Research Report), with a price target of $20.00. The company’s shares closed last Thursday at $4.14. According to TipRanks.com, Fein is